RxDoctor Payments Data

Noah Johnson, MD

Family Medicine · Santee, CANPI 1932215092

Payments from drug & device makers

$18,237in general payments, 2019–2025

Across 915 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$18,08799%
  • Education$1501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)181$3,049
AstraZeneca74$1,965
GSK72$1,485
Lilly USA, LLC77$1,308
Novo Nordisk72$1,066
Boehringer Ingelheim39$1,028
Novartis49$980
Otsuka America Pharmaceutical, Inc.14$648
Pfizer33$639
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)20$512
Sanofi-aventis U.S. LLC23$370
Vanda Pharmaceuticals Inc.20$363
Johnson & Johnson25$359
Axsome Therapeutics, Inc.3$348
Merck18$324
Bayer12$320
Sunovion Pharmaceuticals Inc.19$297
Takeda Pharmaceuticals U.S.A., Inc.16$287
Amgen(2 entities)13$246
Astellas Pharma US Inc8$229
Daiichi Sankyo Inc.15$195
Biohaven Pharmaceutical Holding Company Ltd.8$186
Jazz Pharmaceuticals Inc.6$170
Lundbeck LLC7$146
Amarin Pharma, Inc.6$129
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$105
Seqirus USA Inc5$102
Upsher-smith Laboratories LLC4$97
Abbott5$97
Kowa Pharmaceuticals America, Inc.5$90
Collegium Pharmaceutical, Inc.5$81
Genentech USA, Inc.4$79
Eisai Inc.5$69
Alkermes, Inc.3$60
Idorsia Pharmaceuticals US Inc3$45
Bausch Health US, LLC3$45
Teva Pharmaceuticals USA, Inc.3$43
Actelion Pharmaceuticals US, Inc.2$43
E.r. Squibb & Sons, L.L.C.2$43
Scilex Pharmaceuticals Inc.1$42
Esperion Therapeutics, Inc.2$38
Neurelis, Inc.2$37
Advanced Respiratory, Inc1$33
Cipher Pharmaceuticals US LLC1$30
Nevro Corp.1$25
Dexcom, Inc.1$24
Assertio Therapeutics, Inc.2$23
Alnylam Pharmaceuticals Inc.1$23
Avanir Pharmaceuticals, Inc.1$23
Mylan Specialty L.p.1$22
Supernus Pharmaceuticals, Inc.1$22
Nalpropion Pharmaceuticals LLC1$20
Medtronic1$20
Corcept Therapeutics1$20
Ironwood Pharmaceuticals, Inc1$20
Xeris Pharmaceuticals, Inc.1$19
Biohaven Pharmaceuticals, Inc.1$19
Tactile Systems Technology Inc1$18
Dermira, Inc.1$17
Hologic Sales And Service, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,237 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$88,100
Medicare patients
277
Services billed
3,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide188$223,571
JardianceEmpagliflozin120$144,240
EliquisApixaban69$62,912
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$41,253
XareltoRivaroxaban24$28,071
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr29$27,228
EntrestoSacubitril/Valsartan13$21,655
MounjaroTirzepatide17$21,007
LinzessLinaclotide20$18,564
FarxigaDapagliflozin Propanediol15$15,021
MyrbetriqMirabegron12$13,291
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$13,002
Tresiba Flextouch U-200Insulin Degludec19$9,391
Atorvastatin Calcium727$7,820
Advair HfaFluticasone Propion/Salmeterol18$7,578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,066$223,571188 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,028$150,531131 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,485$68,48178 claims
PfizerEliquis$639$62,91269 claims
Johnson & JohnsonXarelto$359$28,07124 claims
AstraZenecaFarxiga, Brilinta, Symbicort$1,965$24,60943 claims
NovartisEntresto$980$21,65513 claims
Lilly USA, LLCMounjaro$1,308$21,00717 claims
AbbVieLinzess$3,049$18,56420 claims
Astellas Pharma US IncMyrbetriq$229$13,29112 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$287$6,82311 claims
Collegium Pharmaceutical, Inc.Xtampza Er$81$6,18820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Santee

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →